Contents
Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. TransEnterix Inc. shares soared in the extended session Friday after the Food and Drug Administration gave marketing clearance to the company’s robotic surgery device.
The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina. The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users. To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
- Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
- There are an estimated 6 million laparoscopic procedures that take place every year in both the United States and Europe, so the market for the Senhance system seems ripe for the picking.
- The author has not received compensation for writing this article, other than from FXStreet.
- Asensus Surgical, Inc. is a medical device company that is digitizing the interface between the surgeon and the patient through Performance-Guided Surgery.
- Any improvement to robotic vision can only be seen as a positive when it comes to performing surgeries, so it stands to reason as to why investors have shown such excitement as of late.
But, as of Dec. 31, TransEnterix had just $17.5 million in cash on hand. It raised over $100 million via two equity offerings in the past month. It’ll eventually need more capital infusions to keep the lights on. If you’re looking to take a spin in this sector, TransEnterix gives you a stock with a story. I’d encourage you to read what my InvestorPlace colleague, Muslim Farooque wrote about the key differences between the Senhance Surgical System and Intuitive Surgical’s Da Vinci surgical system.
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score forex rebate of 62 would rank higher than 62 percent of all stocks. Sign up for a Robinhood brokerage account to watch TransEnterix and buy and sell other stock and options commission-free. The robotic surgery specialist is helping to enhance the capabilities of surgeons, but its shares may have come too far, too fast.
Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. TransEnterix received approval in Europe on Tuesday for its Intelligent Surgical Unit , which adds machine-vision functions to the Senhance Surgical System. Senhance digital laparoscopic surgery programs in Europe will now have access to this innovative augmented-intelligence technology.
Price and EPS Surprise Chart
ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. TransEnterix Inc. shares surged 12% in premarket trade Tuesday, after the company said it has won U.S. Food and Drug Administration approval for expanded indications for its Senhance Surgical System.
As demand for TRXC stock remains red-hot, it shouldn’t have trouble executing another direct offering. In today’s market, shareholder dilution may not be a major concern. Recent shareholder dilution could affect future performance. But, more importantly, the company’s prior stumbling may signal it falls short of expectations a second time. The last five years has been a rollercoaster ride for its share price. But with the Senhance Surgical System officially launched, that narrative may be about to change.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares. The stock of Transenterix Inc. can try to reach, or even cross these levels in monthly sessions. These are possible Transenterix Inc. weekly share price targets.
Transenterix Inc (TRXC)
Dalmore and Apex Crypto, LLC are not affiliated with any of the Public Holdings subsidiaries. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on ironfx review trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.
The Senhance system is currently only approved for use in specific kinds of surgeries. But, as Alex Sirois noted, the FDA may approve the system for use in general surgery this year. The problem comes for those investors who get stuck in the middle of these trades. Maybe it’s hft arbitrage ea a fear of missing out , but many retail investors are discovering that many stocks trade at very cheap prices for very good reasons. In fact, TransEnterix is likely to be a better option than any of the “meme” stocks that many retail investors have been bidding higher.
And the reality is that many penny stocks carry a low price for a reason. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. Investors are hoping Transenterix can get a share of the nearly 6 million annual laparoscopic surgeries in the U.S. and Europe. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016. Chris Markoch is a freelance financial copywriter who has been covering the market for seven years. Although 2021 may still have some obstacles, it’s likely to be a much better year for elective surgeries in general, and it should provide a boost for companies that focus on robotic surgeries. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.
After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. But at its highs on Wednesday, the stock price had more than doubled following the announcement of its European approval on Tuesday morning. Many investors likely decided to lock in some gains and sell their shares at that point, which could be why TransEnterix’s stock price ended the trading day essentially flat on Wednesday. Yet, this bullish take came out when TRXC stock was trading for 1/3rd of its current share price.
Stock bulls are rejuvenated as no ‘sell’ signals lurk
As its rallied since then, the risk/return proposition may now be less in your favor. Its current market capitalization (around $1.5 billion), compared to the possible size of this market 2 years out, may not look too out of hand. The phenomenon that is the tale of the meme stocks is a tale as old as time. Find a stock that’s trading for pennies pump it higher, and then dump the shares for a profit. On the other side of the trade, you have individuals and in many cases institutional investors, who are shorting the stock when they see it going up. Intraday Data provided by FACTSET and subject to terms of use.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only. On the date of publication, Thomas Niel did not hold any positions in the securities mentioned in this article. Add-ons like the Intelligent Surgical Unit may make it a more commercially appealing product.
That is to say, investors are taking what amounts to a modicum of positive news, and extrapolating potential growth that the company will fail to live up. Many hospitals were forced to cancel or postpone robotic surgeries due to a high census of Covid-19 patients. TransEnterix was forced to rely on secondary stock offerings to raise cash. Despite a surge above $6 in early February, TransEnterix fell into the penny stock range in late 2019 and it stayed there for much of last year.
How to buy TRXC stock on Public
Below are the latest news stories about Transenterix Inc that investors may wish to consider to help them evaluate TRXC as an investment opportunity. TransEnterix, Inc. focuses on the development and commercialization of a robotic assisted surgical system in the United States and internationally. Sign Up NowGet this delivered to your inbox, and more info about our products and services. Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests.
Gold price has started to push higher following a consolidation phase during the Asian trading hours and rose above $1,780 on Wednesday. The benchmark 10-year US Treasury bond yield declined below 3.8% ahead of US data, helping XAUUSD gather bullish momentum. The catalyst was European approval for Transenterix’s Intelligent Surgical Unit or ISU, which provides improved machine-vision functionality for its Senhance system which specializes in laparoscopic surgeries. Any improvement to robotic vision can only be seen as a positive when it comes to performing surgeries, so it stands to reason as to why investors have shown such excitement as of late. There are an estimated 6 million laparoscopic procedures that take place every year in both the United States and Europe, so the market for the Senhance system seems ripe for the picking.
A Reddit user compared Transenterix to Intuitive Surgical, which is a $95 billion company that develops robotic products for improving clinical outcomes of patients through minimally invasive surgery. What TransEnterix does is market the Senhance surgical system (cleared by the U.S. Food and Drug Administration in 2017). Yet, said capital will likely come from dilutive stock offerings. As investor enthusiasm remains sky-high, this may not do much to hurt its share price. But, it will affect how far shares could climb in the years ahead.